Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-01-25

Clinical Trial Update: A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD [Phase 2]

View source ↗

Summary

Phase 2 dose-range finding study of SUN-101 in adults with moderate to severe COPD was completed and results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SUN-101 (glycopyrrolate)

Snippet

Sponsor: Sunovion Respiratory Development Inc. | Conditions: COPD | Phase 2 | Status: COMPLETED | Results posted: 2018-01-25